"Inside the explosive rise of a wellness company outpacing a $200B+ global market"Watch the full Morning Show interview → ...

SIOUX FALLS, SD / ACCESS Newswire / December 2, 2025 / Avel eCare is pleased to announce the appointment of Pat Gundersen as its new Chief Revenue Officer, bringing more than twenty years of ...

This is the first agreement signed by the EIB with a corporate venture capital in the healthcare sector, and is part of the EU strategy to support the development of innovative companies across the ...

IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network COLLEGE PARK, MD – December 1, 2025 - IonQ (NYSE: IONQ), the world’s leading quantum ...

Funds will enable launch of AI-powered R&D center and bring BiPER Tx’s selective BiP (GRP78) inhibitor clinical candidate BPR001-615 a step closer to entering phase 1/2a clinical trial in ...

Responding to the announcement on a landmark UK-US pharmaceuticals deal to safeguard medicine access, Dr Layla McCay, director of policy at the NHS Confederation, said:“Healthcare leaders know that a ...

Responding to the British Medical Association’s announcement that resident doctors will strike for a further five days in the run up to Christmas, Rory Deighton, acute and community care director at ...

Results presented at the 18th Clinical Trials in Alzheimer's Disease (CTAD) meeting, San Diego, December 1-4VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to ...

US agreement removes U.S. tariffs on UK drugs but requires the NHS to pay more for new medicines by raising NICE thresholds ...

As scientists seek to understand the molecular basis of energy production, aging, and disease, one area remains especially elusive: cellular redox metabolites. Finnish biotech company NADMED is ...

TURKU, FI / ACCESS Newswire / December 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel ...

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF ...